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Abstract 
Background: Neuraxial anesthesia is utilized in children of all ages. Local 
anesthetics produce dose-dependent toxicity in certain adult models, but the 
developing spinal cord may also be susceptible to drug-induced apoptosis. In 
postnatal rodents, we examined effects of intrathecal levobupivacaine on 
neuropathology and long-term sensorimotor  outcomes.    
Methods: Postnatal day 3 (P3) or P7 rat pups received intrathecal levobupivacaine 
2.5mg/kg (0.5%) or saline. Mechanical withdrawal thresholds and motor block were 
assessed. Spinal cord tissue analysis included: apoptosis counts (activated-caspase-
3, Fluoro-Jade C) at 24 h; glial reactivity at 7 days; and histopathology in cord and 
cauda equina at 24 h and 7 days. Long-term spinal function in young adults (P35) 
was assessed by hindlimb withdrawal thresholds, electromyography responses to 
suprathreshold stimuli, and gait analysis. 
Results: Intrathecal levobupivacaine produced spinal anesthesia at P3 and P7. No 
increase in apoptosis or histopathological change was seen in the cord or cauda 
equina. In the P3 saline group, activated-caspase-3 (mean±SEM per lumbar cord 
section 6.1±0.3) and Fluoro-Jade C (12.1±1.2) counts were higher than at P7, but 
were not altered by levobupivacaine (P=0.62 and P=0.11, two-tailed Mann-Whitney 
test). At P35, mechanical withdrawal thresholds, thermal withdrawal latency and 
electromyographic reflex responses did not differ across P3 or P7 levobupivacaine or 
saline groups (one way ANOVA with Bonferroni comparisons). Intrathecal 
bupivacaine at P3 did not alter gait.  
Conclusion: Single dose intrathecal levobupivacaine 0.5% did not increase 
apoptosis or produce spinal toxicity in neonatal rat pups. This study provides 
preclinical safety data relevant to neonatal use of neuraxial local anesthesia. 
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Introduction 
Spinal anesthesia in neonates and infants is well established in pediatric 
practice.1,2  Large case series report safe and effective anesthesia and analgesia,3-8 
including use in high risk infants.9,10 Neuraxial anesthesia may have particular 
advantages in preterm-born neonates who are susceptible to postoperative apnoea 
or have co-existing respiratory disease.1,11,12  
Persistent neurological deficits are rare following pediatric regional 
anesthesia,13 but in fact there has been limited detailed follow-up in this patient 
group.1,14,15 Transient neurological symptoms following spinal anesthesia have been 
reported in adults16,17 and in children,2 but neonates and infants are unable to report 
these symptoms. Models have been established for evaluating local anesthetic 
toxicity in adult animals,18 and the importance of also evaluating nerve root 
histopathology in developmental studies has been emphasized.19 A recent study 
reported no histopathologic change in white matter tracts within lumbar spinal cord 
sections following intrathecal racemic bupivacaine at postnatal day (P)7,14 or 21.20 
As in-vivo studies in adult animals show variable neurotoxicity with different local 
anesthetics,21-23 further preclinical evaluation of different preparations during early 
development is also needed.   
Neuraxial anesthesia and analgesia in neonates and infants avoid or reduce 
exposure to general anesthetic agents, that have been reported to increase neuronal 
apoptosis in the developing rodent and primate brain, with associated adverse long-
term cognitive outcomes.24,25 Apoptosis in the central nervous system has a temporal 
profile that varies across brain regions, with different time windows for increased 
susceptibility to the pro-apoptotic effects of certain drugs.26 Prolonged general 
anesthesia, but not intrathecal bupivacaine, at P7 increases apoptosis in both cortex 
and spinal cord, but neither intervention produced long-term motor deficits.20 As our 
previous work demonstrated higher baseline apoptosis in the cord at P3/4, 
predominantly in the dorsal horn,27-29 we have included a younger age group and 
evaluation of sensory outcomes in our toxicicty studies. As different local anesthetics 
produce varying degrees of apoptosis in neuronal cell cultures,30,31 evaluation of 
additional preparations in in-vivo developmental models will further define the safety 
profile of spinal anesthesia in early life.  
Levobupivacaine, the S (-)-enantiomer of bupivacaine, produces reliable and 
effective spinal anesthesia in neonates32,33 and children,34 and is also widely used for 
single-shot caudal blocks35,36 and perioperative epidural infusions37,38 in pediatric 
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practice. Compared with the same dose of racemic bupivacaine, levobupivacaine 
has an improved systemic toxicity profile after intravenous administration39 and 
reduced neurotoxicity following intrathecal administration in some,23 but not all,40 
adult animal studies. Our developmental model of spinal toxicity had sufficient 
sensitivity to demonstrate a relatively wide safety margin following morphine27 and 
clonidine,29 but adverse outcomes following ketamine,28 and will now be the basis for 
further evaluation of local anesthetic toxicity in the neonatal spinal cord.  
The current study evaluates spinal toxicity following intrathecal 
levobupivacaine in neonatal (P3 and P7) rat pups. Evaluation includes: behavioral 
analysis; quantification of apoptosis; and histopathological evaluation of spinal cord 
and cauda equina. Functional outcomes in early adulthood (P35) included sensory 
withdrawal thresholds; electromyographic responses to suprathreshold stimuli during 
anesthesia. Gait analysis following neonatal intrathecal bupivacaine is also 
presented. 
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Materials and Methods 
Animals 
Experiments were carried out according to protocols approved by IACUC 
(Institutional Animal Care and Use Committee) of University of California, San Diego, 
La Jolla, California. Pregnant Holtzman Sprague-Dawley rats (Harlan, Indianapolis, 
IN) were housed in accordance with the National Institute of Health guidelines in a 12 
h light-dark cycle and with free access to standard food and water. Dams were 
monitored, and the day of birth of pups noted. Pups were randomly assigned to 
treatment groups containing equal numbers of males and females at postnatal day 3 
(P3) or day 7 (P7). Body weights of the rat pups were between 8-11 g at P3 and 12-
18 g at P7.  
Additional experiments evaluating long-term spinal reflex function were 
performed in the United Kingdom under personal (SMW) and project licences in 
accordance with the requirements of the United Kingdom Animal (Scientific 
Procedures) Act 1986. Sprague-Dawley dams and litters were bred in-house in the 
Biological Services Unit University College London, and were maintained on a 12-h 
light/dark cycle at constant ambient temperature with free access to food and water. 
Pups were randomly assigned to treatment groups at P3 or P7. Litters were 
restricted to a maximum of 12, with pups weaned into same-sex cages at P21, and 
maintained until P35.  
For all experimental interventions, rat pups were kept on a heating pad to 
maintain body temperature. Care was taken to minimize the duration of maternal 
separation and handling of pups, and this was the same for both control and 
treatment groups. Due to the need to confirm correct intrathecal placement and 
motor block, experimenters were aware of treatment allocation during initial 
behavioral testing. Animals for long-term evaluation of spinal reflex function were 
coded following injections to ensure that the investigator was blinded to initial 
treatment allocation during testing at P35. Similarly, tissue sections were coded and 
the experimenter was unaware of treatment allocation at the time of analysis. 
 
Intrathecal injections and solutions 
 Percutaneous intrathecal injections were performed as previously 
described.27 Under brief isoflurane anesthesia (3%) with oxygen and room air via a 
nose cone, 0.5% levobupivacaine hydrochloride (Chirocaine 50mg/10ml; Abbott 
Laboratories Limited, Maidenhead, Berkshire, United Kingdom) or sterile saline was 
injected intrathecally at the L4-L5 or L5-L6 intervertebral space using a 30 gauge 
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needle connected to a micro-injector and Hamilton syringe. The volume of the 
injectate was 0.5µl/g body weight, which produces spread over low thoracic and 
lumbar segments in rat pups.27 Our pilot experiments confirmed that this volume of 
local anesthetic produced reliable motor block of the hindlimbs. Dose escalation was 
precluded as we restricted analysis to a clinically-available 0.5% preparation, and 
higher volumes (1µl/g) were associated with impaired respiration and increased 
mortality, consistent with previous reports following 0.5% bupivacaine.20,27   
 
Behavioral testing and assessment of spinal reflex function 
Acute effects. In rat pups, baseline mechanical withdrawal threshold was 
determined using calibrated von Frey filaments which apply logarithmically increasing 
pressure (0.4 to 15g). Each von Frey filament was applied five times with 1 sec 
intervals to the dorsal surface of the hindpaw41. The number of evoked withdrawal 
responses to each stimulus of increasing intensity was recorded until a given 
stimulus evoked five responses, or a supra-threshold cut-off pressure was reached 
(10grams at P3; 15grams at P7). Following injection and recovery from anesthesia, 
pups were assessed for visible motor block (failure of hip flexion, dragging of 
hindlimbs, and no response to a suprathreshold mechanical stimulus). Animals were 
only retained for further analysis if dense motor block was apparent following 
levobupivacaine, and motor function was normal following saline. Motor block scores 
(0 = no movement; 1=partial block, 2=full movement) for the left and right hindlimbs 
were added to give a total score between 0 and 4 for each animal20. Mechanical 
withdrawal thresholds were measured in both hindlimbs at 15, 30, 45 and 60 minutes 
following injection, and at 24 hours or 7 days prior to tissue analysis.  
Spinal reflex function at P35. Separate groups of P3 and P7 animals received 
intrathecal 0.5% levobupivacaine 0.5mcl/g or saline as described above. Spinal cord 
function was assessed at 5 weeks of age (P35) by evaluating hindlimb withdrawal 
reflex responses to mechanical and thermal stimuli, with the experimenter blinded to 
initial treatment group.29 Following habituation on an elevated mesh platform, the 
mechanical stimulus (electronic von Frey device; Dynamic Plantar Aesthesiometer, 
Ugo Basile, Comerio, Italy) was applied to the mid-plantar surface of the hindpaw. 
The threshold was averaged from 3 measures of the force (0 to 50 grams; ramp 20 
grams/sec) required to produce hind-limb withdrawal. Thermal withdrawal latency 
was determined using a modified Hargreaves Box (University Anesthesia Research 
and Development Group, University of California San Diego, La Jolla, California) with 
a glass surface (maintained at 30 °C) on which the rats were placed in individual 
Plexiglas cubicles. The thermal nociceptive stimulus from a focused projection bulb 
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positioned below the glass surface was directed to the mid-plantar hindpaw. Latency 
was defined as the time required for the paw to show a brisk withdrawal as detected 
by photodiode motion sensors that stopped the timer and terminated the stimulus. In 
the absence of a response within 20 seconds, the stimulus was terminated (cut-off 
time). Thermal latency was the average of three measures from each hindpaw. 
 To assess sensorimotor reflex function to both threshold and suprathreshold 
stimuli, flexor reflex electromyography recordings from the biceps femoris muscle 
were performed as previously described42,43. In brief, animals were anesthetised with 
halothane (2-4%) in oxygen and a tracheal tube was inserted to facilitate mechanical 
ventilation (Small Animal Ventilator, Harvard Apparatus Ltd). Halothane was reduced 
to 0.9% in oxygen for 30 minutes to ensure equilibration to a stable plane of 
anesthesia, and maintained at this concentration during electromyography 
recordings. Animals were placed in a spinal frame with the left hindpaw secured on a 
fixed platform. Heart rate was continuously monitored and body temperature was 
monitored with a rectal probe and maintained with a thermostatically controlled heat 
source. Bipolar electromyography electrodes (Ainsworks, London, United Kingdom) 
comprising stainless steel 30G needles with a central copper wire core were placed 
through a small skin incision into the belly of the biceps femoris muscle. 
Electromyography responses to mechanical hindpaw stimuli were processed 
(Neurolog System, Digitimer Ltd, Welwyn Garden City, United Kingdom) and 
recorded in 12-second epochs (PowerLab 4S, AD Instruments, Castle Hill, Australia).  
Von Frey hairs were sequentially applied to the plantar surface of the hindpaw up to 
a maximum of hair number 20 (180g) to quantify the response to suprathreshold 
stimuli. 
Gait analysis at P35. In separate experiments, gait analysis was performed at P35 
following intrathecal injection of 0.5% bupivacaine at P3. These experiments were 
performed in conjunction with our previous experiments evaluating effects of 
intrathecal morphine27 and ketamine28, but the local anesthetic results have not been 
previously reported. Gait analysis was performed as the animal crossed the glass 
runway of the CatWalk® system (Noldus Information Technology, Wageningen, The 
Netherlands). Animals commenced a daily training paradigm at P22-25, with runway 
crossings toward food rewards at the farther end. At P35, runway crossings were 
recorded and included in analysis if the maximal time for crossing the 60-cm-long 
section of the runway used for gait recording was ≤2 seconds, and there were no 
intermediate stops during the crossing. Three crossings per animal were analyzed 
using the CatWalk® 7.1.6 software (Noldus Information Technology, Wageningen, 
The Netherlands).    
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Spinal cord tissue preparation and staining  
Tissue analysis was performed either 24 hours or 7 days following injection. 
Rat pups were terminally anesthetized with intraperitoneal injection of 100mg/kg 
pentobarbital and transcardially perfused with saline followed by 4% 
paraformaldehyde. Following laminectomy, the spinal cord and cauda equina were 
dissected, post-fixed in 4% paraformaldehyde overnight, then transferred to 30% 
sucrose and stored at +40C. Transverse sections of lumbosacral spinal cord (7 and 
14 µm) were cut using a cryostat (Leica CM 1800, San Marcos, CA), mounted on 
slides (Fisher Superfrost Plus, Fisher Scientific, Houston, TX), and stored at -300C. 
Using our previously described protocols,27-29 we assessed: histopathology with 
hematoxylin and eosin staining 24hrs and 7 days post-injection; apoptosis with 
activated caspase-3 immunohistochemistry and Fluoro-Jade C staining at 24 hours; 
and glial reactivity by staining with microglial (ionized calcium binding adapter 
molecule 1; Iba-1) and astrocytic (glial fibrillary acidic protein) markers 7 days 
following injection. For histopathological evaluations of the nerve roots, cauda equina 
was cut from the spinal cord 24 hours and 7 days following injection and transferred 
into 2.5% glutaraldehyde in 0.1M PB. 
Activated caspase-3. Immunohistochemistry with an antibody to activated caspase-
3, the final member of an intracellular cascade activated during programmed cell 
death, was performed on tissue 24 hours post-injection. Tris-Buffered Saline was 
used for initial washes and between steps. Slides were incubated in 3% peroxidase 
in methanol for 10 min, blocked with 0.3% Triton X-100 and 5% normal goat serum in 
Tris-Buffered Saline for one hour at room temperature, then incubated overnight at 
4°C with rabbit monoclonal anti-activated caspase 3 (1:100; Cell Signaling, Danvers, 
MA). Biotinylated goat anti-rabbit secondary antibody (Vector, Burlingame, CA) was 
applied at 1:250 for 30 min at room temperature, followed by avidin-biotin-peroxidase 
complex (ABC reagent; Vector Laboratories, Burlingame, CA) for 30 min. Staining 
was developed with 3,3’-diaminobenzidine (DAB; Vector Laboratories, Burlingame, 
CA) for 8 min and then slides were counterstained with hematoxylin, dehydrated and 
coverslipped (Permount, Fischer SP15, Fair Lawn, NJ). At least four sections from 
each animal were counted for caspase-3 immunoreactive cells under the light 
microscope. 
Fluoro-Jade C. Fluoro-Jade C staining was performed in 14µm sections of spinal 
cord 24 hours following injection using an established protocol44. Slides were 
immersed in 1% sodium hydroxide in 80% ethanol, rinsed with 70% ethanol, then 
incubated in 0.06% potassium permanganate. Sections were stained with 0.0002% 
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Fluoro-Jade C (Millipore, Temecula, CA) and 0.01% 4,6-diamidino-2-phenylindole 
(DAPI; Molecular Probes, Eugene, OR) dissolved in 0.1% acetic acid, cleared with 
Citrisolve and coverslipped. Fluoro-Jade C immunfluorescent positive cells in at least 
four sections from each animal were counted under the appropriate wavelength 
fluorescent microscopy.  
Glial fibrillary acidic protein and ionized calcium binding adapter molecule 1 
(Iba1). Spinal cords sections (14 µm thick) 7 days following injection were evaluated 
for glial reactivity with astrocyte (glial fibrillary acidic protein) and microglial (Iba1) 
markers. Following washes with Triton X-100 0.1% in phosphate buffered saline 
(used for rinses throughout), slides were incubated in 5% goat blocking serum at 
room temperature for one hour, followed by mouse anti-glial fibrillary acidic protein 
(1:500; Chemicon, Temecula, CA) and rabbit anti-Iba1 (1:1000; WAKO, Richmond, 
VA) for 48 hours at 40C, and then fluorescent secondary antibodies for 2 hours 
(1:250 goat anti-mouse Alexa 555 and 1:250 goat anti-rabbit Alexa 488; Molecular 
Probes, Eugene, OR). Slides were cover-slipped with Prolong Gold antifade 
mounting media with DAPI (Molecular Probes, Eugene, OR). At least four sections 
from each animal were imaged using standardized exposures and an Olympus BX51 
microscope with appropriate wavelength fluorescence illuminator (Olympus America, 
Inc., Center Valley, PA) equipped with a digital camera and image-capture software. 
The mean intensity of immunofluorescence within a fixed size region of interest in the 
dorsal horn and background intensity was calculated using Image Pro Plus software 
(Media Cybernatics Inc., Silver Spring, MD).29 
Hematoxylin and Eosin. Seven-micron sections of spinal cord from 24 hour and 7 
day survival groups were stained with Hematoxylin (Gill No.2; Sigma Aldrich, St 
Louis, MO) and Eosin (Eosin Y solution Alcoholic; Sigma Aldrich, St Louis, MO). At 
least 4 non-consecutive sections per animals were evaluated for histopathological 
changes (degenerating neurons, tissue necrosis, inflammation or other changes) by 
a neuropathologist experienced in the evaluation of neonatal neurological injury and 
spinal toxicity (MG).27-29,45,46 
Nerve root histology. Neurotoxicologic evaluation of nerve roots of the cauda 
equina was performed 24 hours or 7 days after saline or levobupivacaine 
admnistration in P3 and P7 pups (n=4 per group, total=32 animals). Cauda equina 
was cut from the spinal cord and transferred into 2.5% glutaraldehyde in 0.1M PB. 
The nerve roots were rinsed with 0.1M PB, postfixed in 1% osmium tetroxide, 
dehydrated in serial concentrations of alcohol, and embedded in araldite resin 
according to the recommended procedure47. Transverse, 1-µm-thick sections were 
cut on an automated Leica RM2065 microtome and stained with methylene blue, 
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azure II for light microscopy. Images were taken using Openlab 4.04 software 
(Improvision, Waltham, MA) and examined for pathological change by an investigator 
experienced in nerve pathology (VS).48 
 
Statistical Analysis 
For determination of mechanical withdrawal thresholds in rat pups, the 
number of withdrawal responses was plotted against the mechanical stimulus (force 
expressed as grams on log10 scale). A sigmoidal stimulus-response curve with 
nonvariable slope was constructed using non-linear regression curve fit, and the mid-
point of the curve (50% effective force; EF50) was designated as the mechanical 
withdrawal threshold, as previously described.26,27 For graphical display, data within 
the group were pooled for evaluation of EF50 at 15 minutes as motor block resulted in 
either no response to the maximum mechanical threshold or a sub-maximal 
responses (i.e. less than 5/5 responses to the maximum mechanical stimulus)(Fig. 1 
and 2). To allow analysis of the effect of time and treatment, individual threshold 
values for each animal were calculated at baseline, 30, 45, 60 minutes and 24 hours, 
and the maximum applied force was designated the threshold if motor block was 
present at 15 minutes. Repeated measures two-way ANOVA with Bonferroni’s post 
hoc test was used to evaluate differences between levobupivacaine and saline 
groups. Thresholds seven days following injection of levobupivacaine or saline at P3 
or P7 were compared with unpaired two-tailed Student’s t-test. In P35 rats, 
mechanical withdrawal thresholds and thermal latencies were the mean of 3 values 
for each hindpaw. As data were obtained at the  same age, and were normally 
distributed (Kolmogorov-Smirnov test) continuous variables, all treament groups 
compared with one-way ANOVA with Bonferroni’s post hoc comparisons. In addition, 
thresholds and latencies were  compared with two-way ANOVA with sex and 
treatment as variables, and age at time of injection and treatment as variables. The 
duration of the electromyography response was outlined from the display of the raw 
data and the integral of the root mean square (RMS) of the signal was calculated 
(EMG response)(Chart, Powerlab AD Instruments, Castle Hill, Australia). The 
electromyography response was plotted against the von Frey hair number 
(mechanical stimulus) and the area under the stimulus-response curve (AUC) 
calculated to quantify the overall “reflex response”.42,42 For tissue sections measures 
from at least 4 non-consecutive sections were averaged for each animal, with 
analysis based on n=number of animals and comparison with two-tailed Mann-
Whitney test. Statistical analysis was performed using Prism Version 5.0 (GraphPad, 
San Diego, CA) and P < 0.05 was considered statistically significant. 
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Results 
Intrathecal levobupivacaine produces sensory and motor blockade in rat pups  
Body weights of rat pups were between 8-11 g (mean± SEM 9.75 ± 0.24) at 
P3, and 12-18 g (15.74 ± 0.39) at P7. Baseline mechanical withdrawal thresholds 
were lower at P3 than P7 (1.9±0.2g, n=20 vs 2.7±0.3, n=19; P<0.05 unpaired 2-tailed 
t-test) but did not differ significantly between saline versus levobupivacaine groups 
within age groups (1.9±0.2 vs 2.0±0.3, P=0.66 at P3; 2.5±0.3 vs 2.8±0.4, P=0.41 at 
P7). Dense motor block of the hindlimbs and failure of hip flexion was apparent 5 
minutes following intrathecal levobupivacaine, when animals had recovered from 
anesthesia. Fifteen minutes following injection, bilateral block (motor score 0/4) was 
apparent in 4/9 P3 pups and 6/10 P7 pups; unilateral block (motor score 1/4) in 4/9 
P3 and 3/10 P7 pups; and one animal at each age had partial motor response to a 
suprathreshold mechanical stimulus (motor score 2/4). Animals in which correct 
intrathecal placement could not be confirmed by early dense motor block, or that had 
a motor score of 3 or 4 at 15 minutes, were precluded from further analysis. Motor 
deficits were not apparent in any saline treated animals. 
Fifteen minutes following levobupivacaine in P3 (Fig. 1) and P7 pups (Fig. 2), 
the mechanical stimulus-response curve was shifted to the right and the maximal 
response was reduced due to complete motor block in the majority of animals. Within 
group pooled thresholds were higher in levobupivacaine versus saline groups 15 
minutes following intrathecal injection at both P3 (11.3±1.1 vs 2.0±0.1g, P<0.001, 
two-tailed unpaired two-tailed Student’s t-test) and P7 (14.9±1.6g vs 2.4 ± 0.2g, 
P<0.001). Analysis of individual values with time, similarly demonstrated significant 
differences at 15 minutes (P<0.001 in P3 and P7 animals; two way repeated 
measures ANOVA with Bonferroni post-test). Values did not differ between saline 
and levobupivacaine groups at other time points to 24 hours in P3 pups, but sensory 
block was more prolonged in P7 pups with higher mechanical withdrawal thresholds 
at 30 minutes in the levobupivacaine versus saline group (5.3±1.1 vs 2.8±0.7g, 
P<0.05, two way repeated measures ANOVA with Bonferroni post-test). Withdrawal 
thresholds increased with age, but there were no statistically significant differences 
between groups 7 days following injection of levobupivacaine or saline at P3 (8.4±1.4 
vs 5.8±0.6; P=0.11) or P7 (15.1±2.4 vs. 19.0±3.6g; P=0.38; unpaired two-tailed 
Student’s t-test).  
Intrathecal levobupivacaine, apoptosis and glial reactivity 
The number of activated caspase-3 positive cells in the lumbar spinal cord 
(Fig. 3A) did not differ between saline and levobupivacaine groups 24 hours following 
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injection at P3 or P7 (Fig. 3B). Similarly, numbers of Fluoro-Jade C positive cell 
counts was not altered by intrathecal levobupivacaine (Fig. 3C). Consistent with our 
previous studies, levels of apoptosis where higher at P3 than P7, and were 
predominantly distributed in the dorsal horn (Fig. 3B,C).   
Microglial Iba1 staining 7 days after injection was higher in the P7 saline 
versus levobupivacaine group (P<0.05, two tailed Mann Whitney test), but P7 
levobupivacaine did not differ from animals receiving saline or levobupivacaine at P3 
(P=0.22, Kruskal Wallis test with Dunn’s multiple comparisons)(Fig. 4A,B). Intrathecal 
levobupivacaine at either P3 or P7 did not alter the intensity of staining with the 
astrocytic marker glial fibrillary acidic protein 7 days after injection when compared 
with saline control groups (Fig. 4C,D).  
Histopathological evaluation in the spinal cord and cauda equina 
 There was no evidence of necrosis, gliosis, or inflammation in saline or 
levobupivacine groups at any time point. Scattered apoptotic cells were seen in all 
animals. These were present in greatest numbers in the youngest age group (ie. P3 
animals with 24 hour survival) but did not differ between saline and levobupivacaine 
groups (5.7±0.6 vs 7.2±1.8 per section respectively, P=0.6, Mann Whitney two-tailed 
test). At all older ages and time points (P8, P7 plus 24 hours; P10, P3 plus 7 days; 
P14, P7 plus 7 days), the mean number of apototic cells was less than 2 per section 
in both saline and levobupivacaine groups. 
 Multiple intact myelinated axons were observed in the endoneurium of the 
cauda equina in both levobupivacaine and saline treatment groups in postnatal age 
P3 and P7 day pups (Fig. 5). Mild endoneurial edema, particularly in the 
subperineurial and perivascular spaces was observed in all groups. Enlarged 
cytoplasm of activated Schwann cells, characteristic of their morphology during 
developmental remodeling of myelin in the nerves of P3 and P7 rat pups49, was 
observed in both treatment groups. There were no apparent differences between 
saline and levobupivacaine groups in either P3 or P7 pups. 
Intrathecal levobupivacaine and spinal reflex function in early adulthood 
 Spinal reflex responses at P35 were not altered by neonatal spinal 
anesthesia. Mechanical withdrawal threshold (Fig. 6A) and thermal withdrawal 
latency (Fig. 6B) did not differ significantly between groups receiving intrathecal 
saline or levobupivacaine at either P3 or P7 (P=0.1 and 0.051 respectively, one way 
ANOVA with Bonferroni’s post-hoc comparisons). 
 At P35, males weighed more than females (131 ± 4.5 g vs 116 ± 4.1g), and 
there was a significant main effect of sex (F1,11=6.2, P=0.03), but not of treatment 
(F1,11=2.38, P=0.15; two-way ANOVA with sex and treatment as variables) on body 
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weight. There was no main effect of intrathecal treatment (saline or levobupivacaine) 
(F1,11=0.64, P=0.44) or sex (F1,11=0.05, P=0.83) on mechanical withdrawal threshold. 
Similarly, there was no main effect of treatment (F1,11=0.39, P=0.54) or sex 
(F1,11=0.51, P=0.49) on thermal withdrawal latency at P35 (two-way ANOVA with 
treatment and sex as variables). Age at time of injection (P3 or P7) did not influence 
mechanical withdrawal threshold (F1,28=6.6, P=016) or thermal withdrawal latency 
(F1,28=3.4, P=0.08) in early adulthood (two-way ANOVA with age at time of injection 
and treatment as variables).  
 Spinal reflex sensitivity to suprathreshold mechanical stimuli, quantified from 
the area under the mechanical stimulus versus electromyography response 
relationship (Fig. 6C), did not differ between animals receiving intrathecal 
levobupivacaine or saline at P3 or P7 (P=0.87, one way ANOVA with Bonferroni’s 
post-hoc comparisons; Fig. 6D).  
 Gait analysis using the CatWalk® runway system at P35 was not altered by 
prior intrathecal injection of 0.5% bupivacaine at P3. Static (paw print area) and 
dynamic gait parameters (regularity index, duty cycle, stride length, stability of gait) 
did not differ from animals that received intrathecal saline at P3 (Table 1) or age-
matched naïve controls (as previously reported27).  
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Discussion 
 Single dose intrathecal levobupivacaine produced reliable sensory and motor 
blockade in neonatal rat pups at postnatal day 3 (P3) and P7. Intrathecal 
levobupivacaine did not increase apoptosis in the spinal cord, or produce 
histopathological change in the cord or cauda equina. Neonatal spinal anesthesia did 
not adversely affect spinal cord function in young adulthood (P35), as sensory 
withdrawal reflex thresholds, electromyographic responses to suprathreshold 
hindpaw stimuli, and gait did not differ from litter-mate controls receiving intrathecal 
saline.  
 Neuraxial local anesthetics can be used as an alternative to general 
anesthesia, or as a supplemental technique for peri-operative analgesia, in children 
of all ages, and case series in neonates and infants have recently been 
summarised.1 Excessive absorption or inadvertent vascular injection can result in 
systemic toxicity and neurological and cardiovascular complications. As a result, 
there is increasing use of the stereoisomers levobupivacaine or ropivacaine, which 
have wider therapeutic windows than racemic bupivacaine.50,51 Levobupivacaine 
0.5% produced reliable motor and sensory blockade in P3 and P7 pups. Duration of 
sensory block was shorter in younger animals (P3<P7), as seen following 
bupivacaine (P7<P21).20 Similarly, duration of intrathecal local anesthetic block in 
infants is less than adults, and postulated to be due to age-dependent differences in 
relative volume and more rapid turn-over of cerebrospinal fluid.52   
 Serious neurological complications following neuraxial techniques in children 
are rare,1,53 but complication rates are higher in neonates.7,54 Although technical 
issues in small patients may be a factor, specific evaluation of the relative safety of 
neuraxial drugs in early development is essential. Use of spinal analgesia in 
neonates is increasing in some centres7,8 and may be further encouraged to reduce 
exposure to general anesthetics and the potential risk of increased neuronal 
apoptosis in the developing brain.24,55 However, the developing spinal cord is also 
susceptible to apoptosis, which is increased following prolonged general anesthesia 
at P720,56 and analgesic doses of intrathecal ketamine at P3.28 By contrast, intrathecal 
bupivacaine 3.5mg/kg did not increase neuronal apoptosis or produce 
histopathological change in spinal cord white matter following injection at P7, P14 or 
P21.20 Similarly, intrathecal levobupivacaine 2.5mg/kg did not increase apoptosis at 
P7, but additionally we found no adverse effect at the younger age of P3, when 
baseline apoptosis is higher in spinal cord.28,29 This was confirmed using 3 different 
but complementary methods: antibodies to activated caspase-3 (an enzyme in the 
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apoptotic cascade expressed once the neuron is committed to cell death)57; Fluoro-
Jade C staining (which labels degenerating neurons)44; and identification of apoptotic 
cells under high power microscopy.  
 Clinical concerns regarding local anesthetic toxicity followed reports of cauda 
equina syndrome with continuous spinal anesthesia and high local concentrations of 
lidocaine or tetracaine.58,59 Transient neurological symptoms (pain in gluteal region 
and radiating to legs which usually resolves by the 5th postoperative day) may occur 
following spinal anesthesia; most commonly following lidocaine (relative risk about 
seven times higher than bupivacaine), but there is insufficient data to compare rates 
associated with levobupivacaine or ropivacaine.16 Although there has been limited 
detailed evaluation, transient neurological symptoms (tingling in the feet) have been 
reported following spinal anesthesia in children.2 Such symptoms and subtle motor 
deficits cannot be detected in neonates and infants. This emphasizes the need to 
evaluate comparative local anesthetic toxicity in developmental models.    
 Local anesthetic toxicity has been evaluated using in vivo and in vitro models. 
In cell cultures, including adult dorsal root ganglion neurons from rodents and human 
neuroblastoma cell lines, concentration-dependent toxicity has consistently been 
shown. Local anesthetics produce mitochondrial injury, caspase activation, 
apoptosis, increased calcium influx60 and necrosis at higher concentrations.61 
Although selective sensitivity to lidocaine has been reported,31 cellular toxicity has 
been shown following most local anesthetics, and apoptotic potency correlated with 
lipid solubility rather than chemical structure.30 However, in vitro models may over-
estimate neurotoxicity as isolated cells in culture are more vulnerable (no diffusion 
barriers and no vascular clearance of drug), and  duration of exposure to high 
concentrations is often more prolonged.30,62 Local anesthetics impaired outgrowth of 
developing neurites (increased growth cone collapse) in cultured dorsal root ganglion 
neurons from chick embryo,63 but there has been limited evaluation in developmental 
models. 
 In adult rabbits and rodents, intrathecal local anesthetics can produce signs 
of spinal toxicity, but results vary with dose and drug. Spinal histopathology 
(increased macrophage infiltration, axonal degeneration and myelin changes) 
followed intrathecal 10% lidocaine21 but not equi-effective bupivacaine.64 
Levobupivacaine 5% 0.12mcl/g (approximately 0.6mg/kg) did not produce histology 
in adult rats,65 but a higher dose (approximately 2.8mg/kg) produced white matter 
injury that was similar to procaine but greater than following ropivacaine.23 
Vacuolization and degeneration of neurons in the gray matter has also been 
demonstrated following 10% lidocaine,21 and to a lesser degree following tetracaine, 
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2% bupivacaine and 2% ropivacaine.22 In cauda equina,  histopathology  in adult 
rodents was greater following 6.9mg/kg lidocaine (10%) than after equi-effective 
1.5mg/kg bupivacaine (~2.1%).64 Similar injury scores were reported following high 
dose bupivacaine or levobupivacaine (approximately 10mg/kg total dose).40 The 
current study found no differences in spinal cord or cauda equina histology between 
intrathecal levobupivacaine and saline groups administered at either P3 or P7. 
However, rat pups received a lower dose per body weight (2.5mg/kg), and were 
exposed to a lower drug concentration as a consequence of both the injectate 
concentration (0.5%) and further dilution in the relatively greater cerebrospinal fluid 
volume in pups (8.8mcl/g at P5, 4mcl/g at P30).66 Intrathecal injectates of 0.5mcl/g 
produce spread over thoracic and lumbar segments in rat pups,27 and higher 
volumes of local anesthetic can produce significant respiratory compromise.20 
Consistent with a previous evaluation of intrathecal bupivacaine at P7, P14 and 
P21,20 the maximum dose of levobupivacaine at P3 or P7 did not increase apoptosis 
or produce histopathology. As spinal catheters and prolonged infusions are not 
practical in these small pups, we have suggested intrathecal dose escalation and 
calculation of a therapeutic index (maximum tolerated or minimum toxic dose / 
analgesic dose) to evaluate comparative spinal toxicity in developmental models.1 
The current dose of levobupivacaine produced reversible motor and sensory block 
without toxicity, but dose escalation was limited by side-effects. Therefore, the 
therapeutic index is greater than 1, but we cannot exclude toxicity at higher 
concentrations or doses of levobupivacaine.    
 Assessing effects of neonatal exposure on long-term spinal cord function can 
include several parameters. Prolonged general anesthesia at P7 increased apoptosis 
in the spinal cord, but did not impair motor performance at P30 (assessed by time on 
the Rotarod apparatus).20,56 However, as apoptosis in the post-natal cord is greatest 
in the dorsal horn,67 increased apoptosis may also influence sensory function. 
Intrathecal ketamine at P3 increased apoptosis, reduced mechanical withdrawal 
threshold, and altered static, but not dynamic, gait parameters at P35.28 Local 
anesthetics may have additional toxic effects unrelated to developmental apoptosis, 
that influence both motor and sensory outcomes. In adult animals, changes in 
thermal tail flick latency, mechanical paw pressure withdrawal threshold, and motor 
function have been shown 4 to 7 days following doses of local anesthetic that 
produce tissue histopathology.21,22,40,64,68 Here, single intrathecal doses of 2.5mg/kg 
levobupivacaine at either P3 or P7 did not produce persistent changes in spinal 
reflex withdrawal to mechanical or thermal stimuli, and did not alter quantified 
electromyography responses to suprathreshold mechanical stimuli.  Intrathecal 
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bupivacaine 3.75mg/kg at P7 did not to alter motor function (time on the Rotarod) at 
P30.20 The Catwalk® system allows analysis of sensorimotor co-ordination and both 
static and dynamic components of gait. Following intrathecal bupivacaine at P3, gait 
parameters at P35 did not differ from our previously reported values in age-matched 
naïve or P3 intrathecal saline control animals.27  
 Local anesthetics and spinal analgesics are commonly co-administered to 
improve analgesia or reduce local anesthetic requirements,1,69 but some analgesics 
enhance local anesthetic toxicity in cell culture models. Ropivacaine-induced 
decreases in neuronal viability (adult dorsal root ganglion cell culture) were 
potentiated by midazolam, but not clonidine or buprenorphine.62 Midazolam and 
ketamine both increased lidocaine toxicity (human neuroblastoma and rat astrocyte 
cultures), but sufentanil, clonidine, epinephrine and neostigmine had no effect.70 Our 
in vivo studies demonstrated increased neuronal apoptosis in the neonatal cord 
following ketamine,28 but not clonidine29 or morphine27. Further in vivo developmental 
studies evaluating age- and dose-dependent analgesic efficacy, spinal cord and 
nerve root histology, and long-term function following combinations of spinal 
analgesics and local anesthetic would allow further comparison of the safety profile 
of current clinical regimens. 
 In conclusion, single doses of 0.5% intrathecal levobupivacaine produce 
reliable spinal anesthesia in P3 and P7 neonatal rat pups, but do not increase 
apoptosis or produce histopathological changes in the spinal cord or cauda equina. 
This study provides further preclinical safety data relevant to the use of spinal 
anesthesia in neonates, and supports the use of neuraxial anesthesia as a 
comparison group71 for evaluating outcomes following surgery and anesthesia in 
early life.   Further, these results add to a growing body of data that validate the 
neonatal rat as a robust model for assessing the pathogenic propensity of neuraxial 
agents throughout postnatal development, and the requirement for preclinical 
evaluation of toxicity as part of the rational development of neonatal neuraxial 
therapeutics.1 
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Table 1. Gait Parameters at Postnatal Day (P)35 following Intrathecal Treatment at 
P3 
Treatment Print Area Regularity 
Index 
Duty Cycle Stride 
Length 
Base of 
Support  
saline* 40.3 ± 3.5 99.8 ± 0.2 54.1 ± 1.4 107.5 ± 2.1 27.6 ± 0.7 
bupivacaine 40.5 ± 1.9 99.7 ± 0.3 57.7 ± 1.0 99.6 ± 3.5 31.0 ± 0.93 
 
Legend: P = postnatal day; Print area = surface area of floor contacted by hindpaw; 
Regularity index = index for degree of interlimb co-ordination during gait; Duty cycle 
= ratio between stance duration and full stepcycle duration [stance phase duration / 
(stance + swing phase duration)]; Stride length = distance between placement of 
hindpaw and subsequent placement of same paw; Base of Support = distance 
between two hindpaws measured perpendicular to walking direction; *saline data 
previously reported26. 
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FIGURE LEGENDS 
Fig. 1. Mechanical withdrawal thresholds of postnatal day (P)3 rat pups prior to 
(baseline) and at intervals (15, 30, 45, 60mins and 24hrs) following intrathecal 
injection of saline or 0.5mcl/g of 0.5% levobupivacaine. Graphs represent the log10 
stimulus-response relationship between number of hindlimb withdrawal responses 
(0-5) and mechanical stimulus (grams, g) applied with graded von Frey hairs. At 15 
minutes, thresholds were higher in the levobupivacaine (log EC50 11.3g; 95%CI: 9.2-
13.5) than saline (log EC50 2.0; 95%CI 1.7 to 2.3) group. Data points = pooled mean 
± SEM for saline (n=11) and levobupivacaine (n=9) groups. 
 
Fig. 2. Mechanical withdrawal thresholds of postnatal day (P)7 rat pups prior to 
(baseline) and at intervals (15, 30, 45, 60mins and 24hrs) following intrathecal 
injection of saline or 0.5mcl/g of 0.5% levobupivacaine. Graphs represent the log10 
stimulus-response relationship between number of hindlimb withdrawal responses 
(0-5) and mechanical stimulus (grams, g) applied with graded von Frey hairs. 
Thresholds were higher in the levobupivacaine versus saline group at 15 minutes 
(log EC50 14.9g 95%CI: 11.8-18.0 versus 2.4g; 95%CI 2.0-2.9) and to a lesser 
degree at 30 minutes (log EC50 5.1g 95%CI: 4.3-6.0 versus 2.5g; 95%CI 2.1-3.0) . 
Data points = pooled mean ± SEM for saline (n=9) and levobupivacaine (n=9) 
groups. 
 
Fig. 3. Levels of spinal cord apoptosis are influenced by postnatal age but not by 
intrathecal levobupivacaine.  
(A) Representative section of dorsal horn demonstrating activated caspase-3 positive 
cells 24 hours following saline at postnatal day (P)3 (scale bar=100mm).  
(B) Activated caspase-3 positive (AC-3+ve) cell counts 24 hours after intrathecal 
injection of saline or 0.5% levobupivacaine (l-bupi) in P3 and P7 rat pups. Bars 
represent mean ± SEM, n=4-5 per group. There were no significant differences 
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between saline versus levobupivacaine groups in the number of positive cells in the 
total section (P=0.62) or dorsal horn (P=0.17) at P3 or at P7 (P=0.88 and P=0.66 for 
total and dorsal horn cells respectively; two-tailed Mann-Whitney test). 
(C) Fluoro-Jade C positive (FJ-C+ve) cell counts 24 hours after intrathecal injection 
of saline or 0.5% levobupivacaine in P3 and P7 rat pups. Total numbers in the 
transverse spinal sections and the proportion distributed in the dorsal horn are 
shown. Bars represent mean ± SEM, n=4-5 per group. There were no significant 
differences between saline versus levobupivacaine groups in the number of positive 
cells in the total section (P=0.11) or dorsal horn (P=0.10) at P3 or at P7 (P=0.56 and 
P=0.89 for total and dorsal horn cells respectively; two-tailed Mann-Whitney test). 
 
Fig. 4: Glial reactivity 7 days following intrathecal injection of saline or 
levobupivacaine at postnatal day (P)3 or P7. (A) Representative ionized calcium 
binding adapter molecule 1 (Iba1) immunoreactivity in spinal cord dorsal horn 7 days 
after intrathecal (I.T.) levobupivacaine at P3. Scale bars = 200 µm in low and 40 µm 
in high magnification image. (B) Quantification of mean density of Iba1 
immunoreactivity in dorsal horn revealed no difference between P3 saline and 
levobupivacaine (P=0.24), but increased staining in the P7 intrathecal saline vs 
levobupivacaine group (*P<0.05, two-tailed Mann Whitney test). Bars = mean±SEM, 
n=4-5 per group.  (C) Representative glial fibrillary acidic protein (GFAP) 
immunoreactivity in spinal cord dorsal horn 7 days after I.T. (intrathecal) 
levobupivacaine at P7. Scale bars = 200 µm in low and 40 µm in high magnification 
image. (D) Quantification of GFAP immunoreactivity in the dorsal horn was not 
significantly different following injection at P3 (P=1.0) or P7 (P=0.55; two-tailed Mann 
Whitney test). Bars=mean±SEM, n=4-5 per group. 
 
Fig. 5. Histologic sections of cauda equina nerves 24 hrs or 7 days after intrathecal 
injection of saline or levobupivacaine in postnatal day (P)3 and P7 pups. Transverse, 
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1-µm-thick, plastic-embedded sections stained with methylene blue Azure II at x1400 
magnification. Intact myelinated axons, mild endoneurial edema and activated 
Schwann cells characteristic of an age-appropriate proliferative phenotype were 
observed in all sections.  
 
Fig. 6. Spinal reflex responses to hindpaw stimuli in young adulthood are not altered 
by prior intrathecal levobupivacaine.  
(A) Mechanical withdrawal threshold  at postnatal day (P)35 following intrathecal (IT) 
injection on postnatal day 3 (P3 IT) or 7 (P7 IT) of saline or 0.5% levobupivacaine (l-
bupi). Data points = box and whiskers (5-95 percentile); n=6-8 all groups. Values did 
not differ significantly across treatment groups (P=0.10 one way ANOVA).  
(B) Thermal withdrawal latency at P35 following IT saline or levobupivacaine at P3 or 
P7. Data points = box and whiskers (5-95 percentile); n=6-8 all groups. (P=0.051 one 
way ANOVA). 
(C) (i): Example of electromyography (EMG) recordings in biceps femoris at P35 in 
response to increasing mechanical stimuli (von Frey hair, vFh 17-20), and (ii) plot of 
stimulus-response relationship for quantification of area under the curve (AUC) to 
threshold (vFh 18) and suprathreshold (vFh 19 and 20) stimuli. (D) The quantified 
reflex response (AUC EMG) did not differ between animals treated with saline or 
levobupivacaine at P3 or P7 (P=0.87 one way ANOVA). Data points = mean±SEM; 
n=6 per group.  
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FIGURE 1 
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FIGURE 6 
 
 
	  
